Evidence-based reports have deciphered the involvement of TH17 in cardiovascular disease [220], imposing a careful evaluation that is required while considering antiatherogenic therapy with PD-L1 agonist antibodies, especially when these PD-L1 molecules are expressed on T cells. The gene discussed is CD274; the disease is cardiovascular disorder.